Cas:749255-18-3 1H-pyrrole-3-sulfonic acid manufacturer & supplier

We serve Chemical Name:1H-pyrrole-3-sulfonic acid CAS:749255-18-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1H-pyrrole-3-sulfonic acid

Chemical Name:1H-pyrrole-3-sulfonic acid
CAS.NO:749255-18-3
Synonyms:1H-Pyrrole-3-sulfonicacid;3-PYRROLESULFONIC ACID
Molecular Formula:C4H5NO3S
Molecular Weight:147.15200
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:78.54000
Exact Mass:146.99900
LogP:1.34220

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 1H-Pyrrole-3-sulfonicacid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-PYRROLESULFONIC ACID physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1H-Pyrrole-3-sulfonicacid Use and application,1H-Pyrrole-3-sulfonicacid technical grade,usp/ep/jp grade.


Related News: As you can see, a considerable number of staff is involved in the production phase until an API is finally manufactured. 1H-pyrrole-3-sulfonic acid manufacturer Biogen research chief Alfred Sandrock said the FDA had painstakingly analyzed its clinical trial data over two years before reaching a conclusion. 1H-pyrrole-3-sulfonic acid supplier Biogen research chief Alfred Sandrock said the FDA had painstakingly analyzed its clinical trial data over two years before reaching a conclusion. 1H-pyrrole-3-sulfonic acid vendor Schimpke, an assistant professor in the Division of Minimally Invasive and Bariatric Surgery at Rush Medical College in Chicago, and his colleagues point out that obesity is linked to a considerably higher risk for developing upwards of 40 different serious illnesses, including heart disease and diabetes. 1H-pyrrole-3-sulfonic acid factory Biogen research chief Alfred Sandrock said the FDA had painstakingly analyzed its clinical trial data over two years before reaching a conclusion.